stockportfolio.pro
Stocks / KNSA vs TXG
KNSA vs TXG
Kiniksa Pharmaceuticals International, plc and 10x Genomics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Kiniksa Pharmaceuticals International, plc (KNSA) | 10x Genomics, Inc. (TXG) | |
|---|---|---|
| Market cap | $3.9B | $3.7B |
| Revenue (latest FY) | $677.56M | $642.82M |
| Net income (latest FY) | $59.01M | $-43.54M |
| Revenue growth (5y CAGR) | — | 16.6% |
| Net margin | 8.7% | -6.8% |
| Return on equity | 10.4% | -5.5% |
| P/E ratio | 55.5 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open KNSA — free Open TXG — freeFrequently asked questions
Which is bigger, KNSA or TXG?
Kiniksa Pharmaceuticals International, plc is larger by market capitalization — $3.9B versus $3.7B.
Which grows faster, KNSA or TXG?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.